Home›Pimavanserin

Pimavanserin

Also known as: Nuplazid

Route: Oral

6 interactions on record⛔ Black Box Warning

Pimavanserin has 6 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Certain Cyp3a Substrates, Class 1a Antiarrythmics, Class 3 Antiarrythmics. Patients taking Pimavanserin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 6
Major: 6

Major (6)

Pimavanserin + Certain Cyp3a Substrates— Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia. Avoid combination.
Pimavanserin + Class 1a Antiarrythmics— Concomitant use may add to QT prolongation effects of pimavanserin and increase risk of cardiac arrhythmia.
Pimavanserin + Class 3 Antiarrythmics— Concomitant use may add to QT prolongation effects of pimavanserin and increase risk of cardiac arrhythmia.
Pimavanserin + Macrolide Antibiotics— Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia. Avoid combination.
Pimavanserin + Mao Inhibitors— Increases pimavanserin exposure. Reduce pimavanserin dose to 10 mg once daily when used concomitantly.
Pimavanserin + Strong Or Moderate Cyp3a Inducers— Reduces pimavanserin exposure. Avoid concomitant use.

Pimavanserin + Certain Cyp3a Substrates⚠️Major

Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia. Avoid combination.

Pimavanserin + Class 1a Antiarrythmics⚠️Major

Concomitant use may add to QT prolongation effects of pimavanserin and increase risk of cardiac arrhythmia.

Pimavanserin + Class 3 Antiarrythmics⚠️Major

Concomitant use may add to QT prolongation effects of pimavanserin and increase risk of cardiac arrhythmia.

Pimavanserin + Macrolide Antibiotics⚠️Major

Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia. Avoid combination.

Pimavanserin + Mao Inhibitors⚠️Major

Increases pimavanserin exposure. Reduce pimavanserin dose to 10 mg once daily when used concomitantly.

Pimavanserin + Strong Or Moderate Cyp3a Inducers⚠️Major

Reduces pimavanserin exposure. Avoid concomitant use.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.